Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy

Afzal Ahmad, Poornima Manjrekar, Charu Yadav, Ashish Agarwal, Rukmini Mysore Srikantiah, Anupama Hegde

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This study aimed at evaluation of ischemia-modified albumin (IMA), malondialdehyde (MDA), and advanced oxidative protein products (AOPP) as markers of vascular injury in diabetic nephropathy (DN) with derivation of cutoff values for the same.Materials and methods: Study population comprised 60 diabetes patients and ˂30 controls, with diabetes patients further categorized into three groups based on urine albumin/creatinine ratio (UACR) of,30 mg/g (diabetes without microalbuminuria), 30-300 mg/g (early DN), and ˃300 mg/g of creatinine (overt DN). Serum IMA, MDA, and AOPP were estimated by enzyme-linked immunosorbent assay; HbA1c, serum creatinine, urine albumin, and urine creatinine were estimated using automated analyzers. Statistical analysis was done using analysis of variance, Pearson’s correlation coefficient, and receiver-operating characteristic curve.Results: A statistically significant difference was found in the levels of IMA among patients with early DN (154 ng/mL), diabetes without nephropathy (109.4 ng/mL), and healthy controls (45.7 ng/mL), with highest levels in early DN cases. Similar increase was seen in AOPP as well. A significant correla-tion was observed between IMA and UACR in diabetes without nephropathy (r = 0.448).Conclusion: The present study postulates serum IMA as a novel biomarker for the assessment of disease progression in diabetes even before microal-buminuria, and a cutoff point ≥99 ng/mL can be used for detection of early DN.

Original languageEnglish
Pages (from-to)63-68
Number of pages6
JournalBiomarker Insights
Volume11
DOIs
Publication statusPublished - 02-05-2016

Fingerprint

Vascular System Injuries
Diabetic Nephropathies
Medical problems
Malondialdehyde
Creatinine
Urine
Albumins
Proteins
Immunosorbents
Biomarkers
Analysis of variance (ANOVA)
ROC Curve
Disease Progression
ischemia-modified albumin
Assays
Statistical methods
Analysis of Variance
Enzyme-Linked Immunosorbent Assay
Enzymes
Serum

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Biochemistry, medical

Cite this

@article{c07b17ffbf1543ba97ee18325e87e888,
title = "Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy",
abstract = "This study aimed at evaluation of ischemia-modified albumin (IMA), malondialdehyde (MDA), and advanced oxidative protein products (AOPP) as markers of vascular injury in diabetic nephropathy (DN) with derivation of cutoff values for the same.Materials and methods: Study population comprised 60 diabetes patients and ˂30 controls, with diabetes patients further categorized into three groups based on urine albumin/creatinine ratio (UACR) of,30 mg/g (diabetes without microalbuminuria), 30-300 mg/g (early DN), and ˃300 mg/g of creatinine (overt DN). Serum IMA, MDA, and AOPP were estimated by enzyme-linked immunosorbent assay; HbA1c, serum creatinine, urine albumin, and urine creatinine were estimated using automated analyzers. Statistical analysis was done using analysis of variance, Pearson’s correlation coefficient, and receiver-operating characteristic curve.Results: A statistically significant difference was found in the levels of IMA among patients with early DN (154 ng/mL), diabetes without nephropathy (109.4 ng/mL), and healthy controls (45.7 ng/mL), with highest levels in early DN cases. Similar increase was seen in AOPP as well. A significant correla-tion was observed between IMA and UACR in diabetes without nephropathy (r = 0.448).Conclusion: The present study postulates serum IMA as a novel biomarker for the assessment of disease progression in diabetes even before microal-buminuria, and a cutoff point ≥99 ng/mL can be used for detection of early DN.",
author = "Afzal Ahmad and Poornima Manjrekar and Charu Yadav and Ashish Agarwal and Srikantiah, {Rukmini Mysore} and Anupama Hegde",
year = "2016",
month = "5",
day = "2",
doi = "10.4137/BMI.S39053",
language = "English",
volume = "11",
pages = "63--68",
journal = "Biomarker Insights",
issn = "1177-2719",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy

AU - Ahmad, Afzal

AU - Manjrekar, Poornima

AU - Yadav, Charu

AU - Agarwal, Ashish

AU - Srikantiah, Rukmini Mysore

AU - Hegde, Anupama

PY - 2016/5/2

Y1 - 2016/5/2

N2 - This study aimed at evaluation of ischemia-modified albumin (IMA), malondialdehyde (MDA), and advanced oxidative protein products (AOPP) as markers of vascular injury in diabetic nephropathy (DN) with derivation of cutoff values for the same.Materials and methods: Study population comprised 60 diabetes patients and ˂30 controls, with diabetes patients further categorized into three groups based on urine albumin/creatinine ratio (UACR) of,30 mg/g (diabetes without microalbuminuria), 30-300 mg/g (early DN), and ˃300 mg/g of creatinine (overt DN). Serum IMA, MDA, and AOPP were estimated by enzyme-linked immunosorbent assay; HbA1c, serum creatinine, urine albumin, and urine creatinine were estimated using automated analyzers. Statistical analysis was done using analysis of variance, Pearson’s correlation coefficient, and receiver-operating characteristic curve.Results: A statistically significant difference was found in the levels of IMA among patients with early DN (154 ng/mL), diabetes without nephropathy (109.4 ng/mL), and healthy controls (45.7 ng/mL), with highest levels in early DN cases. Similar increase was seen in AOPP as well. A significant correla-tion was observed between IMA and UACR in diabetes without nephropathy (r = 0.448).Conclusion: The present study postulates serum IMA as a novel biomarker for the assessment of disease progression in diabetes even before microal-buminuria, and a cutoff point ≥99 ng/mL can be used for detection of early DN.

AB - This study aimed at evaluation of ischemia-modified albumin (IMA), malondialdehyde (MDA), and advanced oxidative protein products (AOPP) as markers of vascular injury in diabetic nephropathy (DN) with derivation of cutoff values for the same.Materials and methods: Study population comprised 60 diabetes patients and ˂30 controls, with diabetes patients further categorized into three groups based on urine albumin/creatinine ratio (UACR) of,30 mg/g (diabetes without microalbuminuria), 30-300 mg/g (early DN), and ˃300 mg/g of creatinine (overt DN). Serum IMA, MDA, and AOPP were estimated by enzyme-linked immunosorbent assay; HbA1c, serum creatinine, urine albumin, and urine creatinine were estimated using automated analyzers. Statistical analysis was done using analysis of variance, Pearson’s correlation coefficient, and receiver-operating characteristic curve.Results: A statistically significant difference was found in the levels of IMA among patients with early DN (154 ng/mL), diabetes without nephropathy (109.4 ng/mL), and healthy controls (45.7 ng/mL), with highest levels in early DN cases. Similar increase was seen in AOPP as well. A significant correla-tion was observed between IMA and UACR in diabetes without nephropathy (r = 0.448).Conclusion: The present study postulates serum IMA as a novel biomarker for the assessment of disease progression in diabetes even before microal-buminuria, and a cutoff point ≥99 ng/mL can be used for detection of early DN.

UR - http://www.scopus.com/inward/record.url?scp=84976260362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976260362&partnerID=8YFLogxK

U2 - 10.4137/BMI.S39053

DO - 10.4137/BMI.S39053

M3 - Article

VL - 11

SP - 63

EP - 68

JO - Biomarker Insights

JF - Biomarker Insights

SN - 1177-2719

ER -